Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Center, Single-Arm, Phase II Study Evaluating the Efficacy and Safety of QLS4131 in Combination With Isa-V-CHOP in Previously Untreated, HIV-Negative Patients With Plasmablastic Lymphoma (PBL)

NCT07921615 is registered in ClinicalTrials.gov with Institute of Hematology & Blood Diseases Hospital, China as lead sponsor.

NCT NCT07921615 Not yet recruiting Phase 2 10 participants (estimated) Started 2026

Follow this trial by email Email me the PDF

Get the NCT07921615 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Summary

Not yet recruiting, started December 2026. Interventional study, Phase 2, 10 participants (estimated). Lead sponsor Institute of Hematology & Blood Diseases Hospital, China. Primary measure: Complete response rate (CRR).

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Center, Single-Arm, Phase II Study Evaluating the Efficacy and Safety of QLS4131 in Combination With Isa-V-CHOP in Previously Untreated, HIV-Negative Patients With Plasmablastic Lymphoma (PBL)
Lead sponsor
Institute of Hematology & Blood Diseases Hospital, China
Phase
Phase 2
Overall status
Not yet recruiting
Start date
December 1, 2026
Completion date
December 30, 2028
Enrollment
10 (estimated)
Sites
Not reported

Conditions

MeSH condition names; the registry's own terms follow.

Who could take part, where it ran, who ran it

As filed in ClinicalTrials.gov.

Sex
All
Minimum age
18 Years
Healthy volunteers
No
Study type
Interventional
Lead sponsor
Institute of Hematology & Blood Diseases Hospital, China

Arms

As registered; 1 arm.

Registered arms
Arm Type Interventions
TsAb-treatment group Experimental QLS4131 combined with Isa-V-CHOP
Show registry wording

Eligible patients who meet the inclusion/exclusion criteria will receive QLS4131 combined with the Isa-V-CHOP regimen after enrollment, with each cycle lasting 21 days; efficacy will be assessed after Cycles 2 and 4 and after completion of Cycle 6. After completing 6 cycles and the primary endpoint assessment, patients with advanced-stage disease (Ann Arbor stage III-IV) may receive autologous hematopoietic stem cell transplantation or QLS4131 monotherapy maintenance for 6 cycles; patients with limited-stage disease (stage I-II) may be considered for local radiotherapy.

Primary endpoints

Registered primary outcome measures; 1 primary.

Registered primary endpoints
Measure Time frame
Complete response rate (CRR) 6 months

Lead sponsor's other trials

Institute of Hematology & Blood Diseases Hospital, China, most recent start first.

Similar trials

Same condition (Plasmablastic Lymphoma) and phase, most recent start first.